Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIV4-Outpatient in COVID-19
NCT04498273Phase 3Terminated
- Start
- Sep 2020
- Primary completion
- Aug 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of apixaban, aspirin in coronavirus disease 2019 (COVID-19). Started Sep 2020; status: terminated.
02
Drugs
apixabanaspirin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04498273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04498273.